SCHEMBL6207630

SCHEMBL6207630

CC1C(NC(=O)c2ccc(Cl)cc2)C2CCN1CC2

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 5/20 0.56
HTR3E A5X5Y0 1/20 0.56
HTR3B O95264 1/20 0.56
ALOX15 P16050 1/20 0.56
TSHR P16473 1/20 0.56
HTR3A P46098 1/20 0.56
HTR3D Q70Z44 1/20 0.56
HTR3C Q8WXA8 1/20 0.56
GAA P10253 1/20 0.55
CHRNB2 P17787 2/20 0.55
CHRNA4 P43681 2/20 0.55
KMT2A Q03164 2/20 0.49
MEN1 O00255 1/20 0.49
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
TRPV1 Q8NER1 1/20 0.46
POLB P06746 2/20 0.45
HSD11B1 P28845 1/20 0.43
HRH3 Q9Y5N1 1/20 0.42
ALDH1A1 P00352 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5373596 1.00 CHRNA7 (0.56) CHRNA7HTR3EHTR3BALOX15TSHR
SCHEMBL6882314 0.93 CHRNA7 (0.49) CHRNA7HTR3EHTR3BALOX15TSHR
SCHEMBL6880022 0.93 CHRNA7 (0.49) CHRNA7HTR3EHTR3BALOX15TSHR
SCHEMBL6207641 0.92 GAA (0.63) CHRNA7HTR3EHTR3BALOX15TSHR
SCHEMBL6209384 0.88 LMNA (0.50) CHRNA7HTR3EHTR3BALOX15TSHR
SCHEMBL6287026 0.88 LMNA (0.50) CHRNA7HTR3EHTR3BALOX15TSHR
SCHEMBL6207989 0.88 LMNA (0.50) CHRNA7HTR3EHTR3BALOX15TSHR
SCHEMBL5371792 0.84 CHRNB2 (0.59) CHRNA7CHRNB2CHRNA4KMT2AMEN1
SCHEMBL6883942 0.84 CHRNA7 (0.50) CHRNA7CHRNB2CHRNA4KMT2AMEN1
SCHEMBL6884337 0.83 CHRNA7 (0.46) CHRNA7HTR3EHTR3BALOX15TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1389208-B1 SUBSTITUTED AZABICYCLIC MOIETIES FOR THE TREATMENT OF DISEASE (NICOTINIC ACETHYLCHOLINE RECEPTOR AGONISTS) PHARMACIA & UPJOHN CO LLC (US) 2005-12-28 EP claimed
EP-1389208-A1 SUBSTITUTED AZABICYCLIC MOIETIES FOR THE TREATMENT OF DISEASE (NICOTINIC ACETHYLCHOLINE RECEPTOR ANTAGONISTS) PHARMACIA & UPJOHN COMPANY (US) 2004-02-18 EP claimed
US-20030055043-A1 Substituted azabicyclic moieties for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-03-20 US claimed
WO-2002085901-A1 SUBSTITUTED AZABICYCLIC MOIETIES FOR THE TREATMENT OF DISEASE (NICOTINIC ACETHYLCHOLINE RECEPTOR AGONISTS) PHARMACIA & UPJOHN COMPANY (US) 2002-10-31 WO claimed
EP-1406901-A1 QUINUCLIDINES-SUBSTITUTED-MULTI-CYCLIC-HETEROARYLS FOR THE TREATMENT OF DISEASE PHARMACIA & UPJOHN COMPANY (US) 2004-04-14 EP disclosed
WO-2002100857-A1 QUINUCLIDINES-SUBSTITUTED-MULTI-CYCLIC-HETEROARYLS FOR THE TREATMENT OF DISEASE PHARMACIA & UPJOHN COMPANY (US) 2002-12-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055043-A1 Substituted azabicyclic moieties for the treatment of disease CHRNA1, CHRNA7, CHRNA5 CHRNA7 2/4885HTR3E 1188/4885HTR3B 501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.